Gemifloxacin: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 29: | Line 29: | ||
'''| [[Gemifloxacin clinical studies|Clinical Studies]]''' | '''| [[Gemifloxacin clinical studies|Clinical Studies]]''' | ||
'''| [[Gemifloxacin dosage and administration|Dosage and Administration]]''' | '''| [[Gemifloxacin dosage and administration|Dosage and Administration]]''' | ||
'''| [[Gemifloxacin how supplied|How Supplied]]''' | '''| [[Gemifloxacin how supplied|How Supplied]]''' | ||
'''| [[Gemifloxacin labels and packages|Labels and Packages]]''' | '''| [[Gemifloxacin labels and packages|Labels and Packages]]''' | ||
Latest revision as of 00:38, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
Overview
Gemifloxacin mesylate (trade name Factive®, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.
Category
Quinolone, fourth generation.
US Brand Names
FACTIVE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021158s013lbl.pdf